Germany | Bayern

Zurück zur Suche

Internationale Partnersuche

Innovation & Technologie Angebot

New protein for the diagnosis of renal carcinoma

Country of Origin: Germany
Reference Number: TODE20160804002
Publication Date: 15 August 2016

Summary

A German university identified a new protein, vitemin 3. It enables a novel approach for the diagnosis of benign oncocytomas and their differentiation from malignant renal carcinomas. The university offers a license agreement as well as research cooperation to adapt this diagnoctic procedure to clinical use. This offer addresses companies that devolop diagnostic products in oncology.

Description

Kidney cancer is classified as malignant tumors originating from different renal cells with several subtypes. The cells of these subtypes can mimic a benign kidney tumor, called oncocytoma. The unequivocal differentiation of a benign or malignant carcinoma is essential for planning the adequate operative procedure (tumor removal [oncocytoma] or complete kidney resection with lymph node preparation [malignant kidney cancer]) and potential follow up (not necessary in oncocytoma).

Present immune histology with the protein vimentin is used for differentiation whereas only the malignant renal carcinomas are expected to show positivity for full length vimentin. However, vimentin positivity has also been observed in a series of oncocytoma, making the accuracy and validity of this diagnostic approach questionable for differentiation.

Surprisingly, a German university found a splice isoform of vimentin, namely vimentin3 (Vim3), as an indicator of benign oncocytoma. In addition, the inventors found that renal cell carcinomas (RCCs) are negative for Vim3. Accordingly, Vim3 can be used for the diagnosis of a benign oncocyctoma and for the differentiation of benign oncocytoma from malignant renal cell carcinoma.
The currently used antibodies detect not only the full length vimentin, but also the spliced variant Vim3. This might lead to misdiagnosis of oncocytomas with the consequence of a not adequate therapy of the patients. Therefore, the inventors designed an antibody detecting exclusively the Vim3 isoform.

The university offers a license agreement as well as research cooperation to companies that devolop diagnostic products in oncology. Within the research cooperation the diagnostic procedure should be adapted to clinical use.

Advantages and Innovations

The invention presented improves the current immune histology in the field of renal cell carcinoma. The identified vimentim3 represents a novel approach to differentiate a benign oncocytomas from malignant carcinomas. Apart from the fact that this procedure will improve the diagnosis it will also optimize the treatment of the patients.
In addition to that the inventors have already designed an antibody for use.

Stage Of Development

Prototype available for demonstration

Stage Of Development Comment

A diagnostic test, based on a polyclonal antibody against Vim3, can be applied. The next step will be the development of a routine diagnostic for clinical use. This adaption has to be performed by the partner sought for this technology offer.

Requested partner

The university offers a license agreement as well as research cooperation to adapt this diagnoctic procedure to clinical use. This offer addresses companies that devolop diagnostic products in oncology.

Kooperationsanfrage stellen